VIGLライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:28):

Stats
本日の出来高	18 301.00
平均出来高	88 190.00
時価総額	99.22M
EPS	$0 ( 2024-03-26 )
次の収益日	( $-0.600 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.240
ATR14	$0.0240 (0.91%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-18	Kaufmann Petra	Buy	330 000	Stock Option Grant (Right to Buy)
2024-03-18	Kaufmann Petra	Buy	0
2024-03-01	Booth Bruce	Buy	34 612	Stock Option Grant (Right to Buy)
2024-03-01	Bruhn Suzanne Louise	Buy	24 073	Stock Option Grant (Right to Buy)
2024-03-01	Blanchard Cheryl R	Buy	24 761	Stock Option Grant (Right to Buy)

INSIDER POWER
99.98
Last 93 transactions
Buy: 32 103 135 \| Sell: 31 582 660

ボリューム相関

長: -0.10 (neutral)

短: -0.08 (neutral)

Signal:(45.688) Neutral

Vigil Neuroscience, Inc. 相関

10 最も正の相関
RMRM	0.816

10 最も負の相関
NETE	-0.824
SHSP	-0.81
BOCH	-0.801

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Vigil Neuroscience, Inc. 相関 - 通貨/商品

0.09
( neutral )

0.64
( weak )

0.00
( neutral )

0.11
( neutral )

0.44
( neutral )

-0.07
( neutral )

Vigil Neuroscience, Inc. 財務諸表

Annual	2023
収益:	$0
総利益:	$-399 000 (0.00 %)
EPS:	$-2.13

FY	2023
収益:	$0
総利益:	$-399 000 (0.00 %)
EPS:	$-2.13

FY	2022
収益:	$0
総利益:	$-1.01M (0.00 %)
EPS:	$-2.14

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-1.531

Financial Reports:

No articles found.

Vigil Neuroscience, Inc.

Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystrophy and alzheimer's disease. The company also develops a small molecule TREM2 agonist suitable for oral delivery to treat common neurodegenerative diseases associated with microglial dysfunction. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Cambridge, Massachusetts.